Confirmatory Study of Govorestat in CMT-SORD

Inclusion Criteria: * Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures. * Male and non-pregnant, non-lactating female patients between the ages of 16 and 65 years, inclusive. * Females must be of non-childbearing potential (defined as surgically sterile \[i.e., had a bilateral tubal ligation, hysterectomy, or bilateral oophorectomy ≥6 months prior to the first dose of study drug\] or postmenopausal for ≥1 year \[confirmatory follicle stimulating hormone or FSH test results required\] prior to the first dose of study drug) or agree to use a highly effective form of birth control from Screening until 30 days after the last dose of study drug. * Males must be unable to procreate (defined as surgically sterile \[i.e., had a vasectomy ≥6 months prior to Screening\]) or must agree to use a highly effective form of birth control from Screening through 105 days (sum of 5 half-lives and 90 days interval as per CTFG guidelines) after the last dose of study drug. * Clinical diagnosis of Charcot-Marie-Tooth Type 2 (CMT2) or distal Hereditary Motor Neuropathy (dHMN) due to CMT-SORD confirmed by medical record or written communication by health care professional, elevated blood sorbitol level (\>10,000 ng/mL), and SORD gene analysis report indicating at least one pathogenic mutation. * Patient may be on concomitant medications and dietary supplements; however, they must be on stable…